The presentation of updated interim clinical data at a major oncology conference like ASCO is likely to generate positive investor sentiment. The data on MCLA-145, both as a monotherapy and in combination with pembrolizumab, suggests potential advancements in their oncology pipeline, which could drive the stock price up in the short term.